Teresa López-Fernández is a clinical investigator and senior consultant cardiologist at the University Hospital of La Paz in Madrid, Spain. Dr López-Fernández specialises in cardiac imaging and cardio-oncology. Dr López-Fernández coordinates the Cardio-Oncology Clinic at the University Hospital of La Paz. She is the founder and president of the Spanish Cardio-Oncology Working Group of the Spanish Society of Cardiology (SEC). She is also vice-president of the International Cardio-Oncology Society (ICOS) and was elected president of the ESC Council for Cardio-Oncology. Dr López-Fernández is co-chair of the ESC Guidelines on Cardio-Oncology 2022. Her current research interests focus on the diagnosis and prevention of cardiotoxicity.
CV Raúl Córdoba
Dr Raul Cordoba is Head of the Lymphoma Unit at the Fundacion Jimenez Diaz University Hospital, Madrid, Spain. He obtained his Bachelor of Medicine degree from the Autonomous University of Madrid and went on to specialise in haematology at the University Hospital La Princesa, Madrid. He first started his research in the field of lymphoid neoplasms, achieving his Master’s degree in Molecular Oncology from the Spanish National Cancer Research Centre, Madrid, and his PhD from the Department of Medicine at the Autonomous University of Madrid.Dr Cordoba participated in the first edition of the Certificate of Competence in Lymphoma at Ulm, Germany. He is currently the Principal Investigator for the Haematology Programme of START Madrid-FJD, a unit dedicated exclusively to Phase I trials in oncology.He is the chair of the EHA-Scientific Working Group of “”Aging and Hematology”” of the European Hematology Association (EHA). He has participated as a co-author of the 2022 Guidelines of Cardio-Oncology of the European Society of Cardiology.
Javier De Castro
CV Javier de Castro
Head of the Medical Oncology Section of the Hospital Universitario La Paz in Madrid and Director of the Innovation Unit of the Hospital La Paz Institute for Health Research - IdiPAZ. Associate Professor of Oncology at the Autonomous University of Medicine of Madrid and Co-Director of the Chair of Innovative Medicine.
The main areas of scientific and healthcare interest are focused on the molecular biology of lung cancer and other thoracic tumors, the study of predictive factors of response to cancer treatments using high-throughput techniques and the study of etiopathogenic factors of the disease and supportive care. In particular, he has participated in the clinical development of EGFR and ALK inhibitors, antiangiogenic drugs and immunotherapy in lung cancer. Dr. de Castro has published more than 200 articles in international journals and is a member of ASCO, IASLC and ESMO. He is currently secretary of the board of SEOM (Spanish Society of Medical Oncology).